PMID- 24222136
OWN - NLM
STAT- MEDLINE
DCOM- 20140107
LR  - 20131113
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 33
IP  - 11
DP  - 2013 Nov
TI  - The feasibility and efficacy of stereotactic body radiotherapy for 
      centrally-located lung tumors.
PG  - 4959-64
AB  - AIM: To investigate the toxicity and outcome of stereotactic body radiotherapy 
      (SBRT) for centrally-located lung tumors. PATIENTS AND METHODS: A retrospective 
      review was conducted in 45 consecutive patients with centrally-located lung 
      tumors who underwent SBRT. The incidence rate of adverse events (AEs) and outcome 
      after SBRT for primary (32 patients), metastatic and recurrent (13 patients) lung 
      tumors were evaluated. RESULTS: The median follow-up period was 21.2 months. 
      Except for one patient who had grade 4 gastrointestinal toxicity, no patient 
      exhibited any grade 4-5 AE. The 2-year overall survival of patients with primary 
      non-small cell lung cancer (NSCLC) was significantly better than that of those 
      with metastatic and recurrent tumors of 69.4% vs. 46.9% (p=0.04). The local 
      control rates at two years, for patients in the NSCLC and the 
      metastatic/recurrent groups were 70.9% and 100%, respectively (p=0.98). 
      CONCLUSION: SBRT provided effective treatment for centrally-located lung tumors 
      with tolerable toxicity.
FAU - Takahashi, Wataru
AU  - Takahashi W
AD  - Department of Radiology, University of Tokyo Hospital, 7-3-1, Hongo, Bunkyo-ku, 
      Tokyo, 113-8655 Japan. yamachan07291973@yahoo.co.jp.
FAU - Yamashita, Hideomi
AU  - Yamashita H
FAU - Omori, Mami
AU  - Omori M
FAU - Kitaguchi, Mayuka
AU  - Kitaguchi M
FAU - Shibata-Kobayashi, Shino
AU  - Shibata-Kobayashi S
FAU - Sakumi, Akira
AU  - Sakumi A
FAU - Nakagawa, Keiichi
AU  - Nakagawa K
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Non-Small-Cell Lung/mortality/pathology/*surgery
MH  - Feasibility Studies
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Lung Neoplasms/mortality/pathology/*surgery
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Neoplasm Recurrence, Local/mortality/pathology/*surgery
MH  - Neoplasm Staging
MH  - Prognosis
MH  - *Radiosurgery
MH  - Retrospective Studies
MH  - Survival Rate
OTO - NOTNLM
OT  - Centrally-located lung tumor
OT  - SBRT
OT  - adverse effect
OT  - local control
OT  - lung cancer
EDAT- 2013/11/14 06:00
MHDA- 2014/01/08 06:00
CRDT- 2013/11/14 06:00
PHST- 2013/11/14 06:00 [entrez]
PHST- 2013/11/14 06:00 [pubmed]
PHST- 2014/01/08 06:00 [medline]
AID - 33/11/4959 [pii]
PST - ppublish
SO  - Anticancer Res. 2013 Nov;33(11):4959-64.